Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation

Stem Cell Reviews and Reports

Volumn 10, Issue 3, 2014, Pages 351-375

  Sivanathan, Kisha Nandini ^a,b   Gronthos, Stan ^a   Rojas Canales, Darling ^a   Thierry, Benjamin ^c   Coates, P Toby ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Allogeneic; Allograft rejection; Allotransplantation; Autologous; Cellular therapy; Clinical trials; Immunogenicity; Immunosuppression; Immunosuppressive drugs; Interferon gamma; Mesenchymal stem cells; Modification; Monotherapy; Preactivation; Regeneration; T cells

Indexed keywords

GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; ANIMAL; AUTOTRANSPLANTATION; DRUG EFFECTS; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY; REGENERATIVE MEDICINE;

ANIMALS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84899935769     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9495-2     Document Type: Article

References (163)

1. Rocha, P. N., Plumb, T. J., Crowley, S. D., & Coffman, T. M. (2003). Effector mechanisms in transplant rejection. Immunology Reviews, 196, 51-64.
2. Mellman, I., & Steinman, R. M. (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell, 106(3), 255-258.
3. Sozzani, S., Allavena, P., Vecchi, A., & Mantovani, A. (1999). The role of chemokines in the regulation of dendritic cell trafficking. Journal of Leukocyte Biology, 66(1), 1-9.
4. Mempel, T. R., Henrickson, S. E., & Von Andrian, U. H. (2004). T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature, 427(6970), 154-159.
5. Game, D. S., & Lechler, R. I. (2002). Pathways of allorecognition: implications for transplantation tolerance. Transplant Immunology, 10(2-3), 101-108.
6. Sayegh, M. H., & Turka, L. A. (1998). The role of T-cell costimulatory activation pathways in transplant rejection. The New England Journal of Medicine, 338(25), 1813-1821.
7. Afzali, B., Lombardi, G., & Lechler, R. I. (2008). Pathways of major histocompatibility complex allorecognition. Current Opinion in Organ Transplantation, 13(4), 438-444.
8. Montecalvo, A., Shufesky, W. J., Stolz, D. B., et al. (2008). Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. Journal of Immunology, 180(5), 3081-3090.
9. Rothstein, D. M., & Sayegh, M. H. (2003). T-cell costimulatory pathways in allograft rejection and tolerance. Immunological Reviews, 196, 85-108.
10. Li, X. C., Rothstein, D. M., & Sayegh, M. H. (2009). Costimulatory pathways in transplantation: challenges and new developments. Immunological Reviews, 229(1), 271-293.
11. Divate, S. A. (2000). Acute renal allograft rejection: progress in understanding cellular and molecular mechanisms. Journal of Postgraduate Medicine, 46(4), 293-296.
12. Schwartz, R. H. (1996). Models of T cell anergy: is there a common molecular mechanism? The Journal of Experimental Medicine, 184(1), 1-8.
13. Wood, K. J., & Goto, R. (2012). Mechanisms of rejection: current perspectives. Transplantation, 93(1), 1-10.
14. Tarlinton, D. M., Batista, F., & Smith, K. G. (2008). The B-cell response to protein antigens in immunity and transplantation. Transplantation, 85(12), 1698-1704.
15. Win, T. S., & Pettigrew, G. J. (2010). Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation, 90(2), 113-120.
16. van Leeuwen, M. T., Webster, A. C., McCredie, M. R., et al. (2010). Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. British Medical Journal, 340, c570.
17. de Mattos, A. M., Olyaei, A. J., & Bennett, W. M. (2000). Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. American Journal of Kidney Disease, 35(2), 333-346.
18. Stucker, F., & Ackermann, D. (2011). Immunosuppressive drugs-how they work, their side effects and interactions. Therapeutische Umschau, 68(12), 679-686.
19. Vaes, B., Van't Hof, W., Deans, R., & Pinxteren, J. (2012). Application of multiStem((R)) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Frontiers in Immunology, 3, 345.
20. Raicevic, G., Najar, M., Stamatopoulos, B., et al. (2011). The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunology, 270(2), 207-216.
21. Kronsteiner, B., Wolbank, S., Peterbauer, A., et al. (2011). Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells and Development, 20(12), 2115-2126.
22. Prasanna, S. J., Gopalakrishnan, D., Shankar, S. R., & Vasandan, A. B. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5(2), e9016.
23. Hematti, P. (2008). Role of mesenchymal stromal cells in solid organ transplantation. Transplantation Reviews, 22(4), 262-273.
24. El Haddad, N., Heathcote, D., Moore, R., et al. (2011). Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood, 117(4), 1176-1183.
25. Ries, C., Egea, V., Karow, M., et al. (2007). MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood, 109(9), 4055-4063.
26. Wynn, R. F., Hart, C. A., Corradi-Perini, C., et al. (2004). A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood, 104(9), 2643-2645.
27. Zou, Z., Zhang, Y., Hao, L., et al. (2010). More insight into mesenchymal stem cells and their effects inside the body. Expert Opinion on Biological Therapy, 10(2), 215-230.
28. Caplan, A. I., & Dennis, J. E. (2006). Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry, 98(5), 1076-1084.
29. Togel, F., Hu, Z., Weiss, K., et al. (2005). Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. American Journal of Physiology - Renal Physiology, 289(1), F31-F42.
30. Psaltis, P. J., Paton, S., See, F., et al. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540.
31. Herrera, M. B., Bussolati, B., Bruno, S., et al. (2004). Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. International Journal of Molecular Medicine, 14(6), 1035-1041.
32. Li, X., Yu, X., Lin, Q., et al. (2007). Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. Journal of Molecular and Cellular Cardiology, 42(2), 295-303.
33. Xie, H., Wang, Y., Zhang, H., et al. (2013). Role of injured pancreatic extract promotes bone marrow-derived mesenchymal stem cells efficiently differentiate into insulin-producing cells. PLoS One, 8(9), e76056.
34. Xu, Y. Q., & Liu, Z. C. (2008). Therapeutic potential of adult bone marrow stem cells in liver disease and delivery approaches. Stem Cell Reviews, 4(2), 101-112.
35. Tsai, P. J., Wang, H. S., Lin, C. H., et al. (2013). Intraportal injection of insulin-producing cells generated from human bone marrow mesenchymal stem cells decreases blood glucose level in diabetic rats. Endocrine Research. doi: 10. 3109/07435800. 2013. 797432.
36. Moghadasali, R., Mutsaers, H. A., Azarnia, M., et al. (2013). Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity. Experimental and Toxicologic Pathology, 65(5), 595-600.
37. Selmani, Z., Naji, A., Zidi, I., et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26(1), 212-222.
38. Rasmusson, I., Ringden, O., Sundberg, B., & Le Blanc, K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8), 1208-1213.
39. Augello, A., Tasso, R., Negrini, S. M., et al. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. European Journal of Immunology, 35(5), 1482-1490.
40. Ramasamy, R., Fazekasova, H., Lam, E. W., et al. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83(1), 71-76.
41. Jung, Y. J., Ju, S. Y., Yoo, E. S., et al. (2007). MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy, 9(5), 451-458.
42. Le Blanc, K., Rasmusson, I., Sundberg, B., et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363(9419), 1439-1441.
43. Kebriaei, P., Isola, L., Bahceci, E., et al. (2009). Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15(7), 804-811.
44. Wise, A. F., & Ricardo, S. D. (2012). Mesenchymal stem cells in kidney inflammation and repair. Nephrology, 17(1), 1-10.
45. Longoni, B., Szilagyi, E., Quaranta, P., et al. (2010). Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technology and Therapeutics, 12(6), 435-446.
46. Tan, J., Wu, W., Xu, X., et al. (2012). Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. Journal of American Medical Association, 307(11), 1169-1177.
47. Bartholomew, A., Sturgeon, C., Siatskas, M., et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology, 30(1), 42-48.
48. Le Blanc, K., Tammik, L., Sundberg, B., Haynesworth, S. E., & Ringden, O. (2003). Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scandinavian Journal of Immunology, 57(1), 11-20.
49. Inoue, S., Popp, F. C., Koehl, G. E., et al. (2006). Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation, 81(11), 1589-1595.
50. Ding, Y., Xu, D., Feng, G., et al. (2009). Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes, 58(8), 1797-1806.
51. Han, K. H., Kang, H. G., Gil, H. J., et al. (2010). The immunosuppressive effect of embryonic stem cells and mesenchymal stem cells on both primary and secondary alloimmune responses. Transplant Immunology, 23(3), 141-146.
52. Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., et al. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 108(6), 2114-2120.
53. Zhou, H. P., Yi, D. H., Yu, S. Q., et al. (2006). Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplantation Proceedings, 38(9), 3046-3051.
54. Zangi, L., Margalit, R., Reich-Zeliger, S., et al. (2009). Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells, 27(11), 2865-2874.
55. Wu, H., Wen, D., & Mahato, R. I. (2013). Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model. Molecular Therapy, 21(9), 1778-1786.
56. Di Nicola, M., Carlo-Stella, C., Magni, M., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838-3843.
57. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815-1822.
58. Mougiakakos, D., Jitschin, R., Johansson, C. C., et al. (2011). The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood, 117(18), 4826-4835.
59. Nguyen, T., Arthur, A., Hayball, J., & Gronthos, S. D. (2013). EphB and ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. Stem Cells and Development, 22(20), 2751-2764.
60. Sioud, M., Mobergslien, A., Boudabous, A., & Floisand, Y. (2011). Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. International Journal of Oncology, 38(2), 385-390.
61. Sioud, M. (2011). New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scandinavian Journal of Immunology, 73(2), 79-84.
62. Sioud, M., Mobergslien, A., Boudabous, A., & Floisand, Y. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scandinavian Journal of Immunology, 71(4), 267-274.
63. Lepelletier, Y., Lecourt, S., Renand, A., et al. (2010). Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells and Development, 19(7), 1075-1079.
64. Wada, N., Bartold, P. M., & Gronthos, S. (2011). Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Stem Cells and Development, 20(4), 647-659.
65. Le Blanc, K., Rasmusson, I., Gotherstrom, C., et al. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scandinavian Journal of Immunology, 60(3), 307-315.
66. Luz-Crawford, P., Kurte, M., Bravo-Alegria, J., et al. (2013). Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Research and Therapy, 4(3), 65.
67. Batten, P., Sarathchandra, P., Antoniw, J. W., et al. (2006). Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Engineering, 12(8), 2263-2273.
68. Sheng, H., Wang, Y., Jin, Y., et al. (2008). A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research, 18(8), 846-857.
69. Luz-Crawford, P., Noel, D., Fernandez, X., et al. (2012). Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One, 7(9), e45272.
70. Xue, Q., Luan, X. Y., Gu, Y. Z., et al. (2010). The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells and Development, 19(1), 27-38.
71. Najar, M., Raicevic, G., Jebbawi, F., et al. (2012). Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunology Letters, 146(1-2), 50-56.
72. Opitz, C. A., Litzenburger, U. M., Lutz, C., et al. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells, 27(4), 909-919.
73. Akiyama, K., Chen, C., Wang, D., et al. (2012). Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell, 10(5), 544-555.
74. Holmannova, D., Kolackova, M., Kondelkova, K., et al. (2012). CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec Králové), 55(1), 12-17.
75. Gorczynski, R. M., Chen, Z., Khatri, I., & Yu, K. (2011). Graft-infiltrating cells expressing a CD200 transgene prolong allogeneic skin graft survival in association with local increases in Foxp3(+)Treg and mast cells. Transplant Immunology, 25(4), 187-193.
76. Gorczynski, R. M., Chen, Z., He, W., et al. (2009). Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. Journal of Immunology, 183(3), 1560-1568.
77. Beyth, S., Borovsky, Z., Mevorach, D., et al. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood, 105(5), 2214-2219.
78. Zhang, W., Ge, W., Li, C., et al. (2004). Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells and Development, 13(3), 263-271.
79. Jiang, X. X., Zhang, Y., Liu, B., et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105(10), 4120-4126.
80. Li, F. R., Wang, X. G., Deng, C. Y., et al. (2010). Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clinical and Experimental Immunology, 161(2), 357-363.
81. Chen, H. W., Chen, H. Y., Wang, L. T., et al. (2013). Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene Chemokines. Journal of Immunology, 190(10), 5065-5077.
82. Liu, W. H., Liu, J. J., Wu, J., et al. (2013). Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One, 8(1), e55487.
83. Wang, Q., Sun, B., Wang, D., et al. (2008). Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scandinavian Journal of Immunology, 68(6), 607-615.
84. Ge, W., Jiang, J., Arp, J., et al. (2010). Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation, 90(12), 1312-1320.
85. Spaggiari, G. M., & Moretta, L. (2012). Interactions between mesenchymal stem cells and dendritic cells. Advances in Biochemical Engineering/Biotechnology. doi: 10. 1007/10_2012_154.
86. Du Rocher, B., Mencalha, A. L., Gomes, B. E., & Abdelhay, E. (2012). Mesenchymal stromal cells impair the differentiation of CD14(++) CD16(-) CD64(+) classical monocytes into CD14(++) CD16(+) CD64(++) activate monocytes. Cytotherapy, 14(1), 12-25.
87. Lai, H. Y., Yang, M. J., Wen, K. C., et al. (2010). Mesenchymal stem cells negatively regulate dendritic lineage commitment of umbilical-cord-blood-derived hematopoietic stem cells: an unappreciated mechanism as immunomodulators. Tissue Engineering Part A, 16(9), 2987-2997.
88. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576-6583.
89. Djouad, F., Charbonnier, L. M., Bouffi, C., et al. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25(8), 2025-2032.
90. Chen, L., Zhang, W., Yue, H., et al. (2007). Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells and Development, 16(5), 719-731.
91. Aldinucci, A., Rizzetto, L., Pieri, L., et al. (2010). Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. Journal of Immunology, 185(9), 5102-5110.
92. English, K., Barry, F. P., & Mahon, B. P. (2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunology Letters, 115(1), 50-58.
93. Chiesa, S., Morbelli, S., Morando, S., et al. (2011). Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 108(42), 17384-17389.
94. Li, H., Guo, Z., Jiang, X., et al. (2008). Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells, 26(10), 2531-2541.
95. Zhao, Z. G., Xu, W., Sun, L., et al. (2012). Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunological Investigations, 41(2), 183-198.
96. Zhang, B., Liu, R., Shi, D., et al. (2009). Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood, 113(1), 46-57.
97. Weng, J. Y., Huang, X., Lai, P. L., et al. (2012). A method for induction of mouse CD8alpha(+);CD11b(+);jagged2(high);regulatory dendritic cells with mesenchymal stem cells in vitro. Chinese Journal of Cellular and Molecular Immunology, 28(6), 568-571.
98. Berman, D. M., Willman, M. A., Han, D., et al. (2010). Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes, 59(10), 2558-2568.
99. Karussis, D., Karageorgiou, C., Vaknin-Dembinsky, A., et al. (2010). Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology, 67(10), 1187-1194.
100. English, K., Ryan, J. M., Tobin, L., et al. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clinical and Experimental Immunology, 156(1), 149-160.
101. Hsu, W. T., Lin, C. H., Chiang, B. L., et al. (2013). Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-gamma+CD4+ regulatory T cells to control transplant arteriosclerosis. Journal of Immunology, 190(5), 2372-2380.
102. Patel, S. A., Meyer, J. R., Greco, S. J., et al. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. Journal of Immunology, 184(10), 5885-5894.
103. Bacigalupo, A., Valle, M., Podestà, M., et al. (2005). T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Experimental Hematology, 33(7), 819-827.
104. Jorgensen, C., Djouad, F., Fritz, V., et al. (2003). Mesenchymal stem cells and rheumatoid arthritis. Joint, Bone, Spine, 70(6), 483-485.
105. Neef, K., Choi, Y. H., Weichel, A., et al. (2012). The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy, 14(6), 670-678.
106. Bocelli-Tyndall, C., Bracci, L., Spagnoli, G., et al. (2007). Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology, 46(3), 403-408.
107. Perez-Simon, J. A., Tabera, S., Sarasquete, M. E., et al. (2009). Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy, 11(6), 698-705.
108. Rasmusson, I., Uhlin, M., Le Blanc, K., & Levitsky, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82(4), 887-893.
109. Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005). Mesenchymal stem cells avoid allogeneic rejection. Journal of Inflammation, 2, 8.
110. Ankrum, J., & Karp, J. M. (2010). Mesenchymal stem cell therapy: two steps forward, one step back. Trends in Molecular Medicine, 16(5), 203-209.
111. Badillo, A. T., Beggs, K. J., Javazon, E. H., Tebbets, J. C., & Flake, A. W. (2007). Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biology of Blood and Marrow Transplantation, 13(4), 412-422.
112. Rafei, M., Birman, E., Forner, K., & Galipeau, J. (2009). Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Molecular Therapy, 17(10), 1799-1803.
113. Schu, S., Nosov, M., O'Flynn, L., et al. (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 16(9), 2094-2103.
114. Griffin, M. D., Ritter, T., & Mahon, B. P. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Human Gene Therapy, 21(12), 1641-1655.
115. Griffin, M. D., Ryan, A. E., Alagesan, S., et al. (2013). Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunology and Cell Biology, 91(1), 40-51.
116. Sbano, P., Cuccia, A., Mazzanti, B., et al. (2008). Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Archives of Dermatological Research, 300(3), 115-124.
117. Casiraghi, F., Azzollini, N., Cassis, P., et al. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. Journal of Immunology, 181(6), 3933-3946.
118. Popp, F. C., Eggenhofer, E., Renner, P., et al. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transplant Immunology, 20(1-2), 55-60.
119. Eggenhofer, E., Steinmann, J. F., Renner, P., et al. (2011). Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transplant Immunology, 24(3), 157-163.
120. Eggenhofer, E., Renner, P., Soeder, Y., et al. (2011). Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transplant Immunology, 25(2-3), 141-147.
121. Jia, Z., Jiao, C., Zhao, S., et al. (2012). Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model. Experimental Eye Research, 102, 44-49.
122. Seifert, M., Stolk, M., Polenz, D., & Volk, H. D. (2012). Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Frontiers in Immunology, 3, 202.
123. Ge, W., Jiang, J., Baroja, M. L., et al. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. American Journal of Transplantation, 9(8), 1760-1772.
124. Solari, M. G., Srinivasan, S., Boumaza, I., et al. (2009). Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. Journal of Autoimmunity, 32(2), 116-124.
125. Krampera, M., Glennie, S., Dyson, J., et al. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101(9), 3722-3729.
126. Chan, W. K., Lau, A. S., Li, J. C., et al. (2008). MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Experimental Hematology, 36(11), 1545-1555.
127. Polchert, D., Sobinsky, J., Douglas, G., et al. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. European Journal of Immunology, 38(6), 1745-1755.
128. Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386-398.
129. Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141-150.
130. Tobin, L. M., Healy, M. E., English, K., & Mahon, B. P. (2013). Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clinical and Experimental Immunology, 172(2), 333-348.
131. Erkers, T., Nava, S., Yosef, J., Ringden, O., & Kaipe, H. (2013). Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. Stem Cells and Development, 22(19), 2596-2605.
132. Duijvestein, M., Wildenberg, M. E., Welling, M. M., et al. (2011). Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells, 29(10), 1549-1558.
133. Meisel, R., Zibert, A., Laryea, M., et al. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood, 103(12), 4619-4621.
134. Munn, D. H., Zhou, M., Attwood, J. T., et al. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281(5380), 1191-1193.
135. Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clinical and Experimental Immunology, 149(2), 353-363.
136. Francois, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Molecular Therapy, 20(1), 187-195.
137. Wada, N., Menicanin, D., Shi, S., Bartold, P. M., & Gronthos, S. (2009). Immunomodulatory properties of human periodontal ligament stem cells. Journal of Cellular Physiology, 219(3), 667-676.
138. Freeman, G. J., Long, A. J., Iwai, Y., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine, 192(7), 1027-1034.
139. English, K., Barry, F. P., Field-Corbett, C. P., & Mahon, B. P. (2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology Letters, 110(2), 91-100.
140. Chou, H. S., Hsieh, C. C., Charles, R., et al. (2012). Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells. Transplantation, 93(3), 272-282.
141. Francisco, L. M., Salinas, V. H., Brown, K. E., et al. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of Experimental Medicine, 206(13), 3015-3029.
142. Fallarino, F., Asselin-Paturel, C., Vacca, C., et al. (2004). Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. Journal of Immunology, 173(6), 3748-3754.
143. Lee, S., Szilagyi, E., Chen, L., et al. (2012). Activated mesenchymal stem cells increase wound tensile strength in aged mouse model via macrophages. The Journal of Surgical Research, 181(1), 20-24.
144. Kortesidis, A., Zannettino, A., Isenmann, S., et al. (2005). Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood, 105(10), 3793-3801.
145. Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106(13), 4057-4065.
146. Gieseke, F., Schutt, B., Viebahn, S., et al. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood, 110(6), 2197-2200.
147. Potian, J. A., Aviv, H., Ponzio, N. M., Harrison, J. S., & Rameshwar, P. (2003). Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. Journal of Immunology, 171(7), 3426-3434.
148. Gotherstrom, C., Lundqvist, A., Duprez, I. R., et al. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 13(3), 269-278.
149. Campeau, P. M., Rafei, M., Francois, M., et al. (2009). Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Molecular Therapy, 17(2), 369-372.
150. Wang, G. Q., Xu, J. R., Wang, R., et al. (2006). Inhibitory effect of mesenchymal stem cells carrying murine beta defensin 2 on malignant ascites in mice. Chinese Journal of Cancer, 25(6), 657-662.
151. Ren, G., Liu, Y., Zhao, X., et al. (2013). Tumor resident mesenchymal stromal cells endow naive stromal cells with tumor-promoting properties. Oncogene. doi: 10. 1038/onc. 2013. 387.
152. Nishimura, K., Semba, S., Aoyagi, K., Sasaki, H., & Yokozaki, H. (2012). Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology, 79(6), 290-306.
153. Rosland, G. V., Svendsen, A., Torsvik, A., et al. (2009). Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research, 69(13), 5331-5339.
154. Breitbach, M., Bostani, T., Roell, W., et al. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts. Blood, 110(4), 1362-1369.
155. Kunter, U., Rong, S., Boor, P., et al. (2007). Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. Journal of the American Society of Nephrology, 18(6), 1754-1764.
156. Prigozhina, T. B., Khitrin, S., Elkin, G., et al. (2008). Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Experimental Hematology, 36(10), 1370-1376.
157. Du, J., Zhou, L., Chen, X., et al. (2012). IFN-gamma-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. The International Journal of Biochemistry Cell Biology, 44(8), 1305-1314.
158. Munn, D. H., & Mellor, A. L. (2007). Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. The Journal of Clinical Investigation, 117(5), 1147-1154.
159. Zhang, X. M., Jiao, C. N., Jia, Z., et al. (2012). Investigation of the role of mesenchymal stem cells on keratoplasty rejection. Chinese Journal of Ophthalmology, 48(8), 733-738.
160. Perico, N., Casiraghi, F., Introna, M., et al. (2011). Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clinical Journal of the American Society of Nephrology, 6(2), 412-422.
161. Peng, Y., Ke, M., Xu, L., et al. (2013). Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation, 95(1), 161-168.
162. Reinders, M. E., de Fijter, J. W., Roelofs, H., et al. (2013). Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Translational Medicine, 2(2), 107-111.
163. Perico, N., Casiraghi, F., Gotti, E., et al. (2013). Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant International, 26(9), 867-878.